Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-10 01:38:52 EDT

Explore

PostsPeople
LatestRanked
@newsen.bsky.socialOct 6, 2026, 6:29 AM

Lundbeck Advances Parkinson's Research with New Data on Lu AF28996 #USA #Parkinson's_Disease #Lundbeck #Valby #Lu_AF28996

@newsen.bsky.socialOct 6, 2026, 6:18 AM

Lundbeck Unveils Promising Phase Ib Results for Lu AF28996 in Advanced Parkinson's Disease #Denmark #Parkinson's_Disease #Lundbeck #Valby #Lu_AF28996

@newsen.bsky.socialOct 2, 2026, 6:44 AM

Lundbeck to Present Groundbreaking Movement Disorder Research at MDS® 2026 Conference #Denmark #Lundbeck #Valby #Amlenetug #MDS_2026

@newsen.bsky.socialOct 2, 2026, 6:32 AM

Lundbeck's Insights on Movement Disorders at MDS® 2026: Focus on MSA and Parkinson's Disease #Denmark #Movement_Disorders #Lundbeck #MSA #Valby

@newsen.bsky.socialOct 1, 2026, 6:32 AM

Lundbeck's Phase IV THRIVE Trial Results Show Promise for Eptinezumab in Migraine Treatment #Denmark #Lundbeck #Valby #Vyepti #Eptinezumab

@newsen.bsky.socialOct 1, 2026, 6:22 AM

Lundbeck's Phase IV THRIVE Trial Reveals Promising Results for VYEPTI® in Migraine Patients #Denmark #Lundbeck #Valby #Migraine #Vyepti

@newsen.bsky.socialSep 25, 2026, 10:03 AM

Lundbeck Relocates US Headquarters and Launches Innovation Hub in Greater Boston #United_States #Boston #Lundbeck #Innovation_Hub

@newsen.bsky.socialSep 25, 2026, 7:15 AM

Lundbeck Announces New Global Innovation Hub in Greater Boston, Relocating US Headquarters #United_States #Lundbeck #Neuroscience #Greater_Boston

@newsen.bsky.socialSep 25, 2026, 7:15 AM

Lundbeck to Move US Headquarters and Launch Innovation Hub in Greater Boston #USA #Lundbeck #Neuroscience #Greater_Boston #Innovation_Hub

@newsen.bsky.socialSep 16, 2026, 6:30 AM

Lundbeck Celebrates Marketing Authorization for Innovative Migraine Treatment Vyepti® in Japan #Japan #Tokyo #Lundbeck #migraine_prevention #Eptinezumab

@newsen.bsky.socialSep 15, 2026, 7:36 AM

Last Participant Randomized in Phase III DEEp SEA Trial for Bexicaserin in Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby

@newsen.bsky.socialSep 15, 2026, 7:36 AM

Lundbeck Reaches Significant Milestone in Bexicaserin Trial for Dravet Syndrome #Denmark #Dravet_Syndrome #Lundbeck #bexicaserin #Valby

@newsen.bsky.socialSep 11, 2026, 8:31 AM

Lundbeck's Asedebart Receives FDA Orphan Drug Designation for Cushing's Syndrome #Denmark #Lundbeck #Valby #Cushing's_Syndrome #asedebart

@newsen.bsky.socialSep 11, 2026, 8:31 AM

Lundbeck's Asedebart Receives Orphan Drug Status for Rare Hormonal Disorder #USA #Lundbeck #Valby #Cushing's_Syndrome #asedebart

@newsen.bsky.socialSep 3, 2026, 7:43 AM

Lundbeck Unveils Key Insights on Bexicaserin's Unique Mechanism at the European Epilepsy Congress #Denmark #Lundbeck #bexicaserin #Valby #DEEp_Program

@newsen.bsky.socialSep 3, 2026, 7:42 AM

Lundbeck to Showcase Bexicaserin's Innovative Dual Action Mechanism at European Epilepsy Congress #Denmark #Lundbeck #bexicaserin #Valby #Epilepsy_Congress